Myrtelle

Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases. The company owns a proprietary platform, intellectual property, and a portfolio of programs and technologies supporting innovative gene therapy approaches for neurological disorders. Myrtelle has reached an exclusive global licensing agreement with Pfizer for its Canavan disease program.